This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Axovant Sciences, Inc.
Drug Names(s): GSK-742457, GSK742457, SB-742457, SB742457, Intepirdine
Description: GSK742457 is a selective 5-HT6 receptor antagonist. Preclinical data suggests that the 5-HT6 receptor is found mainly in the central nervous system with little or no expression in peripheral tissues, which may result in greater drug selectivity with fewer side effects. Some areas the 5-HT6 receptor is found in are important for learning and memory. In preclinical models, blockade of the receptor improves cognitive function, and also reduces signs thought to reflect anxiety and depression. Blockade is accompanied by enhancement of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. The receptor may also be involved in food intake.
Roivant and GlaxoSmithKline
In January 2015 Roivant Neurosciences has entered into an agreement with GlaxoSmithKline (GSK) for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders. Under the GSK Agreement Roivant is also obligated to pay a fixed 12.5% royalty based on net sales of RVT-101, subject to reduction on account of expiration of patent and regulatory exclusivity or upon generic entry.
Roivant and Axovant
Axovant Sciences is a wholly-owned subsidiary of Roivant Sciences. Axovant's lead drug candidate is RVT-101.
Partners: Roivant Sciences Ltd GlaxoSmithKline plc
Additional information available to subscribers only: